Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Preferred Stock
Beginning balance at Dec. 31, 2018	$ (1,484)	$ 0	$ 51	$ 0	$ (1,535)	$ 6,905
Beginning balance (in shares) at Dec. 31, 2018		537,635				19,565,217
Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs						$ 17,956
Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)						30,183,947
Issuance of Series A Preferred Stock in payment of licensing fee						$ 619
Issuance of Series A Preferred Stock in payment of licensing fee (shares)						1,672,240
Issuances of common stock to licensor institutions	748	$ 1	747
Issuances of common stock to licensor institutions (in shares)		673,562
Vesting of restricted common stock	$ 1	$ 1
Vesting of restricted common stock (in shares)	537,635	643,241
Repayment of shareholder loan	$ 24		24
Unrealized gain (loss) on available-for-sale securities	9			9
Stock-based compensation	446		446
Net loss	(19,297)				(19,297)
Ending balance at Dec. 31, 2019	(19,553)	$ 2	1,268	9	(20,832)	$ 25,480
Ending balance (in shares) at Dec. 31, 2019		1,854,438				51,421,404
Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs						$ 36,792
Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)						49,749,167
Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112						$ 62,888
Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)						78,348,461
Additional issuances of common stock to licensor institutions	487		487
Additional issuances of common stock to licensor institutions (in shares)		187,867
Vesting of restricted common stock	$ 1	$ 1
Vesting of restricted common stock (in shares)	537,635	537,635
Exercise of stock options	$ 11		11
Exercise of stock options (in shares)		5,849
Unrealized gain (loss) on available-for-sale securities	(1)			(1)
Stock-based compensation	850		850
Net loss	(45,704)				(45,704)
Ending balance at Dec. 31, 2020	$ (63,909)	$ 3	2,616	8	(66,536)	$ 125,160
Ending balance (in shares) at Dec. 31, 2020	2,585,789	2,585,789				179,519,032
Issuance of Series B convertible preferred stock, net of issuance costs of $241						$ 93,759
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)						77,163,022
Conversion of convertible preferred stock to common stock upon closing of initial public offering	$ 218,919	$ 28	218,891			$ (218,919)
Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)		27,720,923				(256,682,054)
Issuance of common stock from initial public offering, net of issuance costs of $25,098	281,584	$ 16	281,568
Issuance of common stock from initial public offering, net of issuance costs of (in shares)		16,141,157
Issuances of common stock to licensor institutions	$ 32,490	$ 1	32,489
Issuances of common stock to licensor institutions (in shares)		878,098
Vesting of restricted common stock (in shares)	537,633	537,633
Exercise of stock options	$ 966	$ 1	965
Exercise of stock options (in shares)	599,838	599,838
Purchase of common stock under ESPP	$ 780		780
Purchase of common stock under ESPP(shares)		48,297
Unrealized gain (loss) on available-for-sale securities	(236)			(236)
Stock-based compensation	7,072		7,072
Net loss	(120,314)				(120,314)
Ending balance at Dec. 31, 2021	$ 357,352	$ 49	$ 544,381	$ (228)	$ (186,850)
Ending balance (in shares) at Dec. 31, 2021	48,511,735	48,511,735